These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8256454)

  • 1. Epidemiology, biochemistry and some results with treatment of postmenopausal osteoporosis.
    Hassager C; Christiansen C
    Wien Med Wochenschr; 1993; 143(14-15):389-91. PubMed ID: 8256454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anabolic steroids in postmenopausal osteoporosis.
    Need AG; Durbridge TC; Nordin BE
    Wien Med Wochenschr; 1993; 143(14-15):392-5. PubMed ID: 8256455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate.
    Erdtsieck RJ; Pols HA; van Kuijk C; Birkenhäger-Frenkel DH; Zeelenberg J; Kooy PP; Mulder P; Birkenhäger JC
    J Bone Miner Res; 1994 Feb; 9(2):277-83. PubMed ID: 8140941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
    Bolanca S; Korsić M; Dekanić D; Cvijetić S
    Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.
    Need AG; Horowitz M; Bridges A; Morris HA; Nordin BE
    Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anabolic steroids in corticosteroid-induced osteoporosis.
    Adami S; Rossini M
    Wien Med Wochenschr; 1993; 143(14-15):395-7. PubMed ID: 8256456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of osteoporosis with hormone replacement therapy.
    Christiansen C
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():45-54. PubMed ID: 8499959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular neridronate in postmenopausal women with low bone mineral density.
    Adami S; Gatti D; Bertoldo F; Sartori L; Di Munno O; Filipponi P; Marcocci C; Frediani B; Palummeri E; Fiore CE; Costi D; Rossini M
    Calcif Tissue Int; 2008 Nov; 83(5):301-7. PubMed ID: 18946626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of anabolic steroids on osteoporosis].
    Adachi M; Takayanagi R
    Clin Calcium; 2008 Oct; 18(10):1451-9. PubMed ID: 18830042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of osteoporosis.
    Mulloy AL; Weinstein RS
    J Med Assoc Ga; 1994 Apr; 83(4):227-30. PubMed ID: 8006552
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
    Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mineralization of bone tissue: a forgotten dimension in osteoporosis research.
    Boivin G; Meunier PJ
    Osteoporos Int; 2003; 14 Suppl 3():S19-24. PubMed ID: 12730799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug treatment of osteoporosis (in the woman)].
    Ziegler R
    Ther Umsch; 1998 Nov; 55(11):696-701. PubMed ID: 9865146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.